Chapters (209)
- Title Page
- Copyright Notice
- Dedication
- PART 1
- CHAPTER 1
- CHAPTER 2
- CHAPTER 3
- INTERLUDE 1
- CHAPTER 4
- INTERLUDE 2
- CHAPTER 5
- INTERLUDE 3
- CHAPTER 6
- CHAPTER 7
- INTERLUDE 4
- CHAPTER 8
- CHAPTER 9
- CHAPTER 10
- CHAPTER 11
- CHAPTER 12
- CHAPTER 13
- INTERLUDE 5
- CHAPTER 14
- INTERLUDE 6
- PART 2
- CHAPTER 15
- INTERLUDE 7
- CHAPTER 16
- CHAPTER 17
- CHAPTER 18
- CHAPTER 19
- INTERLUDE 8
- CHAPTER 20
- CHAPTER 21
- CHAPTER 22
- CHAPTER 23
- CHAPTER 24
- CHAPTER 25
- CHAPTER 26
- CHAPTER 27
- CHAPTER 28
- CHAPTER 29
- CHAPTER 30
- CHAPTER 31
- CHAPTER 32
- INTERLUDE 9
- CHAPTER 33
- CHAPTER 34
- CHAPTER 35
- PART 3
- CHAPTER 36
- CHAPTER 37
- CHAPTER 38
- CHAPTER 39
- CHAPTER 40
- CHAPTER 41
- CHAPTER 42
- CHAPTER 43
- CHAPTER 44
- CHAPTER 45
- CHAPTER 46
- INTERLUDE 10
- CHAPTER 47
- CHAPTER 48
- CHAPTER 49
- CHAPTER 50
- CHAPTER 51
- INTERLUDE 11
- CHAPTER 52
- CHAPTER 53
- CHAPTER 54
- CHAPTER 55
- CHAPTER 56
- CHAPTER 57
- INTERLUDE 12
- CHAPTER 58
- CHAPTER 59
- CHAPTER 60
- CHAPTER 61
- CHAPTER 62
- CHAPTER 63
- CHAPTER 64
- CHAPTER 65
- CHAPTER 66
- CHAPTER 67
- CHAPTER 68
- CHAPTER 69
- CHAPTER 70
- CHAPTER 71
- PART 4
- CHAPTER 72
- CHAPTER 73
- CHAPTER 74
- CHAPTER 75
- INTERLUDE 13
- CHAPTER 76
- CHAPTER 77
- CHAPTER 78
- CHAPTER 79
- CHAPTER 80
- CHAPTER 81
- INTERLUDE 14
- CHAPTER 82
- CHAPTER 83
- CHAPTER 84
- CHAPTER 85
- CHAPTER 86
- PART 5
- CHAPTER 87
- CHAPTER 88
- CHAPTER 89
- CHAPTER 90
- CHAPTER 91
- CHAPTER 92
- CHAPTER 93
- CHAPTER 94
- CHAPTER 95
- CHAPTER 96
- CHAPTER 97
- CHAPTER 98
- CHAPTER 99
- CHAPTER 100
- CHAPTER 101
- CHAPTER 102
- CHAPTER 103
- CHAPTER 104
- CHAPTER 105
- CHAPTER 106
- CHAPTER 107
- CHAPTER 108
- CHAPTER 109
- CHAPTER 110
- CHAPTER 111
- CHAPTER 112
- CHAPTER 113
- CHAPTER 114
- CHAPTER 115
- CHAPTER 116
- PART 6
- CHAPTER 117
- CHAPTER 118
- CHAPTER 119
- CHAPTER 120
- CHAPTER 121
- CHAPTER 122
- CHAPTER 123
- CHAPTER 124
- CHAPTER 125
- CHAPTER 126
- CHAPTER 127
- CHAPTER 128
- CHAPTER 129
- CHAPTER 130
- CHAPTER 131
- CHAPTER 132
- CHAPTER 133
- CHAPTER 134
- CHAPTER 135
- CHAPTER 136
- CHAPTER 137
- CHAPTER 138
- CHAPTER 139
- CHAPTER 140
- CHAPTER 141
- CHAPTER 142
- PART 7
- CHAPTER 143
- CHAPTER 144
- CHAPTER 145
- CHAPTER 146
- CHAPTER 147
- CHAPTER 148
- CHAPTER 149
- CHAPTER 150
- CHAPTER 151
- CHAPTER 152
- CHAPTER 153
- CHAPTER 154
- CHAPTER 155
- CHAPTER 156
- CHAPTER 157
- CHAPTER 158
- CHAPTER 159
- CHAPTER 160
- CHAPTER 161
- CHAPTER 162
- CHAPTER 163
- CHAPTER 164
- CHAPTER 165
- CHAPTER 166
- CHAPTER 167
- CHAPTER 168
- CHAPTER 169
- CHAPTER 170
- CHAPTER 171
- CHAPTER 172
- CHAPTER 173
- CHAPTER 174
- CHAPTER 175
- CHAPTER 176
- CHAPTER 177
- CHAPTER 178
- CHAPTER 179
- EPILOGUE
- THE RELENTLESS PLAYLIST
- Acknowledgments
- Also by Jonathan Maberry
- ABOUT THE AUTHOR
- Newsletter Sign-up
Coleman held up a small white packet about half the size of a business card and less than half an inch thick. “According to their clinical records, something like this is intended to be surgically implanted just beneath the skin of each Fixer. And this is an expanded polytetrafluoroethylene pouch that contains hundreds of millions of cells.”
“What type of cells?” asked Church.
“Well, you see, boss, that’s the really interesting part. RNA-Seq showed that they were most likely chromaffin cells. Those are the cells in the adrenal cortex that are responsible for the release of catecholamines.”
“Cate…?” began Wilson, fumbling with it. Coleman stepped right in.
“Catecholamines are the molecules responsible for the body’s fight-or-flight response, which was interesting by itself. But when we dug down and did whole genome sequencing, we found a number of genetically inserted tet-on promoters. Specifically, they were attached to inserted versions of DOPA decarboxylase, dopamine β-hydroxylase, and phenylethanolamine N-methyltransferase.”
“I have no idea what that means.”
Coleman, who was in gear and very excited, tried to scale it down, but he was a lab rat and very rarely had to explain these things to ordinary mortals. “Tet-on promoters are a little bit of DNA that can be used to control when a gene is expressed. Think of it as a light switch for a gene. But this switch is flipped by adding tetracycline. It has been used in biotechnology for a long time, but this isn’t just some off-the-shelf version. This is highly specialized to turn on very fast and make huge amounts of the genes. And the genes they control are the genes in the synthetic pathway to turn L-Dopa into norepinephrine and adrenaline.”
“But … but…,” fumbled Nikki, “why put the cells in the pouches? Why not just inject them somewhere into the PMC?”
“Because the pouch protects the cells from the immune system of the person it is implanted into, so there is no rejection,” explained Coleman. “The pouch lets small molecules and liquid back and forth, but it doesn’t allow cells in or out. There is a clinical trial underway right now where similar technology is being used to encapsulate insulin-secreting cells to treat type 1 diabetes. However, in this case, they are using the pouches as small bioreactors to make huge amounts of norepinephrine and adrenaline but only in the presence of tetracycline. L-Dopa is a synthetic precursor for those hormones, so that makes sense, too.”
“Okay,” Nikki said. “I think I actually understood that part.”
“Still clinging on by my fingernails,” Wilson said under his breath.
“So the capsules under the skin are filled with cells that have been engineered so that the presence of this antibiotic causes them to create huge amounts of norepinephrine and adrenaline. The combination of those two hormones is what is believed to cause hysterical strength. That’s the kind of thing where a mom lifts a car off her baby or whatever.”